A Topical Non Steroidal Anti-inflammatory for Rosacea

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,568,458.00
Award Year:
2009
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI062034-02
Agency Tracking Number:
AI062034
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SIGNUM BIOSCIENCES
SIGNUM BIOSCIENCES, 7 DEER PARK DR, STE H, MONMOUTH JUNCTION, NJ, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
144196354
Principal Investigator:
JOEL GORDON
(732) 329-6344
JSGORDON@SIGNUMBIO.COM
Business Contact:
EDUARDO PEREX
() -
eperez@signumbio.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs modulate heterotrimeric G-protein coupled receptor (GPCR) signaling pathways, representing a novel class of topical anti-inflammatory compounds whose action is restricted to the site of a pplication. Studies performed in the Phase I proposal demonstrate that IPC analogs have a wide spectrum of anti-inflammatory activities with a superior safety profile to glucocorticoids. Signum's proof of concept IPC analog, AFC, inhibited erythema (rednes s) in a double blind, vehicle controlled cosmetic human use study. More potent IPC analogs serve as attractive drug development candidates for reducing erythema and treating rosacea. Several IPC analogs identified from Signum's screening program are attrac tive candidates for preclinical development. The proposed Phase II research plan will identify one lead compound and two backups for preclinical development and will establish the analytical methods, process development and formulation that are necessary. Furthermore, these studies will determine the preclinical safety profile of the lead compound by performing metabolic, pharmacokinetic, toxicology and safety pharmacology studies. Together, the data generated from these studies will allow Signum to prepare and submit an IND for treatment of rosacea. PUBLIC HEALTH RELEVANCE: Rosacea is a common, chronic cutaneous condition afflicting millions of individuals. FDA approved treatments have yielded mixed results, often leaving patients with significant levels of facial redness. Successful pharmaceutical development of IPC analog anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea redness.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government